Ad is loading...
DASCX
Price
$20.35
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
VISVX
Price
$50.61
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

DASCX vs VISVX

Header iconDASCX vs VISVX Comparison
Open Charts DASCX vs VISVXBanner chart's image
Dean Small Cap Value
Price$20.35
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Vanguard Small Cap Value Index I
Price$50.61
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
DASCX vs VISVX Comparison Chart
Loading...
View a ticker or compare two or three
VS
DASCX vs. VISVX commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DASCX is a Buy and VISVX is a Buy.

FUNDAMENTALS
Fundamentals
VISVX has more cash in the bank: 57.6B vs. DASCX (218M). VISVX pays higher dividends than DASCX: VISVX (1.90) vs DASCX (1.78). DASCX was incepted earlier than VISVX: DASCX (28 years) vs VISVX (27 years). DASCX is a more actively managed with annual turnover of: 77.00 vs. VISVX (16.00). DASCX has a lower initial minimum investment than VISVX: DASCX (1000) vs VISVX (3000). VISVX annual gain was more profitable for investors over the last year : 30.04 vs. DASCX (17.93). VISVX return over 5 years is better than : 62.14 vs. DASCX (51.82).
DASCXVISVXDASCX / VISVX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence28 years27 years-
Gain YTD9.17417.71252%
Front LoadN/AN/A-
Min. Initial Investment1000300033%
Min. Initial Investment IRAN/AN/A-
Net Assets218M57.6B0%
Annual Yield % from dividends1.781.9093%
Returns for 1 year17.9330.0460%
Returns for 3 years14.8616.9288%
Returns for 5 years51.8262.1483%
Returns for 10 years33.53109.8331%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EFXT9.240.20
+2.21%
Enerflex Ltd
RVSN0.440.01
+1.60%
Rail Vision Ltd
CAG27.170.05
+0.18%
Conagra Brands
FULC2.97-0.02
-0.67%
Fulcrum Therapeutics
KYMR43.51-0.54
-1.23%
Kymera Therapeutics